Ophthotech Corp (OPHT) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- US stocks set for higher open as surprise payrolls fall cools rate-hike bets
- US nonfarm payrolls fall in July; unemployment rate eases to 4.1%
- Oil prices drop as investors weigh potential Hormuz deal between Iran and Gulf states
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Stocks close lower as investors eye Mideast talks, earnings
- Apollo to acquire easyJet for £5.7B in cash deal
- Nielsen to acquire DoubleVerify in merger deal
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Ophthotech Reports Second Quarter 2015 Financial and Operating Results
August 5, 2015 7:30 AM EDTConference Call and Webcast Today, August 5, 2015, at 8:00 a.m. ET
NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq: OPHT) today announced financial results for the second quarter ended June 30, 2015 and provided an update on the Companys business and product development programs.
Program Highlights
In May 2015, Ophthotech provided updates on the Companys two Phase 3 trials of Fovista® in combination with Lucentis® (ranibizumab) in patients with wet Age-Related Macular Degeneration (AMD). Completion of enrollment of the first Phase 3 trial was announced. In... More
